Literature DB >> 23364811

Rapid molecular diagnosis of measles virus infection in an epidemic setting.

Yanne Michel1, Kenda Saloum, Claire Tournier, Béatrice Quinet, Ludovic Lassel, Alice Pérignon, Emmanuel Grimprel, Ricardo Carbajal, Astrid Vabret, François Freymuth, Antoine Garbarg-Chenon, Aurélie Schnuriger.   

Abstract

During the 2011 measles outbreak in Paris (France), patients with clinical suspicion of measles were tested for virological confirmation of measles virus (MV) infection. To assess the practical value of molecular diagnosis in an epidemic setting, 171 oral fluid samples and 235 serum samples collected from 270 patients were tested prospectively for MV-RNA using a novel one-step real-time RT-PCR assay including an internal control. Serum samples were also tested for MV-specific IgG and IgM antibodies. MV infection was confirmed by detection of MV-RNA and/or MV-IgM for 229 of the 270 patients. The results for the 102 cases with both serum and oral fluid samples available were used to compare the techniques. The detection rate of MV-RNA by RT-PCR was 98% (100/102) for oral fluid and 95% (97/102) for serum samples. The detection rate of MV-IgM was 85% (87/102). Negative MV-IgM results were observed mostly for serum samples collected early after the onset of the rash. A MV-RNA standard of known concentration obtained by in vitro transcription was used to quantify MV-RNA in samples. MV-RNA copy numbers were significantly higher in oral fluid than in serum samples, but did not correlate with time of sampling (within 1 week after the onset of the rash), patient age, or vaccination status. During the early stage of infection, the MV-RNA viral load in serum was lower in patients positive than in those negative for MV-IgG. In conclusion, the one-step real-time RT-PCR assay is a simple and sensitive tool suitable for MV diagnosis within hours.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23364811     DOI: 10.1002/jmv.23515

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  p53 regulates CD46 expression and measles virus infection in myeloma cells.

Authors:  Anne Lok; Geraldine Descamps; Benoit Tessoulin; David Chiron; Marion Eveillard; Catherine Godon; Yannick Le Bris; Astrid Vabret; Celine Bellanger; Laurent Maillet; Sophie Barillé-Nion; Marc Gregoire; Jean-François Fonteneau; Steven Le Gouill; Philippe Moreau; Frederic Tangy; Martine Amiot; Agnes Moreau-Aubry; Catherine Pellat-Deceunynck
Journal:  Blood Adv       Date:  2018-12-11

2.  Laboratory methods supporting measles surveillance in Queensland, Australia, 2010-2017.

Authors:  Jamie L McMahon; Judith A Northill; Mitchell Finger; Michael Lyon; Stephen B Lambert; Ian M Mackay
Journal:  Access Microbiol       Date:  2020-01-27

3.  External Quality Assessment for the Detection of Measles Virus by Reverse Transcription-PCR Using Armored RNA.

Authors:  Dong Zhang; Yu Sun; Tingting Jia; Lei Zhang; Guojing Wang; Rui Zhang; Kuo Zhang; Guigao Lin; Jiehong Xie; Lunan Wang; Jinming Li
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

4.  Real-Time PCR for Measles Virus Detection on Clinical Specimens with Negative IgM Result in Morocco.

Authors:  Touria Benamar; Latifa Tajounte; Amal Alla; Fatima Khebba; Hinda Ahmed; Mick N Mulders; Abdelkarim Filali-Maltouf; Rajae El Aouad
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

Review 5.  Public health responses during measles outbreaks in elimination settings: Strategies and challenges.

Authors:  Paul A Gastañaduy; Emily Banerjee; Chas DeBolt; Pamela Bravo-Alcántara; Samia A Samad; Desiree Pastor; Paul A Rota; Manisha Patel; Natasha S Crowcroft; David N Durrheim
Journal:  Hum Vaccin Immunother       Date:  2018-07-11       Impact factor: 3.452

6.  Comprehensive Bioinformatics Analysis of the Immune Mechanism of Dendritic Cells Against Measles Virus.

Authors:  Lili Jia; Rongqiang Zhang
Journal:  Med Sci Monit       Date:  2019-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.